Literature DB >> 17690011

Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors.

Oliver Hofnagel1, Birgit Luechtenborg, Gabriele Weissen-Plenz, Horst Robenek.   

Abstract

The uptake of oxidized lipoproteins via scavenger receptors and the ensuing formation of foam cells are key events during atherogenesis. Foam cell formation can be reduced by treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). The efficacy of statins is evidently due not only to their cholesterol-lowering properties, but also to lipid-independent pleiotropic effects. This review focuses on lipid-independent pleiotropic effects of statins that influence foam cell formation during atherogenesis, with special emphasis on oxidative pathways and scavenger receptor expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690011     DOI: 10.1016/j.bbalip.2007.06.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Arachidonic acid-modified lovastatin discoidal reconstituted high density lipoprotein markedly decreases the drug leakage during the remodeling behaviors induced by lecithin cholesterol acyltransferase.

Authors:  Hongliang He; Lisha Liu; Hui Bai; Ji Wang; Yan Zhang; Wenli Zhang; Mengyuan Zhang; Zimei Wu; Jianping Liu
Journal:  Pharm Res       Date:  2014-01-22       Impact factor: 4.200

2.  Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-κB pathway.

Authors:  Ge-fei Ma; Song Chen; Lei Yin; Xiang-dong Gao; Wen-bing Yao
Journal:  Acta Pharmacol Sin       Date:  2013-12-16       Impact factor: 6.150

3.  CD36 binds oxidized low density lipoprotein (LDL) in a mechanism dependent upon fatty acid binding.

Authors:  Anthony G Jay; Alexander N Chen; Miguel A Paz; Justin P Hung; James A Hamilton
Journal:  J Biol Chem       Date:  2015-01-01       Impact factor: 5.157

4.  Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis.

Authors:  Allison B Reiss; David W Wan; Kamran Anwar; Joan T Merrill; Peter A Wirkowski; Nidhi Shah; Bruce N Cronstein; Edwin S L Chan; Steven E Carsons
Journal:  Exp Biol Med (Maywood)       Date:  2009-01-14

Review 5.  Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease.

Authors:  Ana García-Lafuente; Eva Guillamón; Ana Villares; Mauricio A Rostagno; José Alfredo Martínez
Journal:  Inflamm Res       Date:  2009-04-21       Impact factor: 4.575

6.  CXCL16 and oxLDL are induced in the onset of diabetic nephropathy.

Authors:  Paul Gutwein; Mohamed Sadek Abdel-Bakky; Kai Doberstein; Anja Schramme; Janet Beckmann; Liliana Schaefer; Kerstin Amann; Anke Doller; Nicole Kämpfer-Kolb; Abdel-Aziz H Abdel-Aziz; El Sayed M El Sayed; Josef Pfeilschifter
Journal:  J Cell Mol Med       Date:  2009-05-01       Impact factor: 5.310

7.  Specific cellular incorporation of a pyrene-labelled cholesterol: lipoprotein-mediated delivery toward ordered intracellular membranes.

Authors:  Gérald Gaibelet; Sophie Allart; François Tercé; Vincent Azalbert; Justine Bertrand-Michel; Safouane Hamdi; Xavier Collet; Stéphane Orlowski
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

Review 8.  The Effects of Statin Therapy on Oxidized LDL and Its Antibodies: A Systematic Review and Meta-Analysis.

Authors:  Tannaz Jamialahmadi; Fatemeh Baratzadeh; Željko Reiner; Massimo R Mannarino; Vladimiro Cardenia; Luis E Simental-Mendía; Matteo Pirro; Gerald F Watts; Amirhossein Sahebkar
Journal:  Oxid Med Cell Longev       Date:  2022-08-01       Impact factor: 7.310

9.  Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice.

Authors:  Sander S Rensen; Veerle Bieghs; Sofia Xanthoulea; Evi Arfianti; Jaap A Bakker; Ronit Shiri-Sverdlov; Marten H Hofker; Jan Willem Greve; Wim A Buurman
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.